Live
- Formula 1: Russell pips Sainz to take pole in Las Vegas GP
- People voted for ideology, rejected dynasty: Sudhanshu Trivedi on Maha victory
- AP, Telangana to receive rains for next three days as low pressure to turn depression
- Kailash Gahlot inducted into BJP’s Delhi election panel
- With state elections over, Indian stock market heads for stability
- Mahayuti's Ladki Bahin Brahmastra demolishes MVA in Maharashtra
- Actor and Youth Ambassador Darasing Khurana Highlights Mental Health Issues with Singapore PM
- Heavy FII selling in India to taper off soon, say market watchers
- Esports Mania Grips India: What are the Trends Fueling this Growth?
- AI-Powered CRM: Shaping the Future of Customer Relationship Management
Dr Reddy's announces commercial launch of 2-DG
Dr Reddy's announces commercial launch of 2-DG (Twitter)
Dr. Reddys, a leading multinational pharmaceutical company today announced the commercial launch of 2-deoxy-D-glucose (2-DG).
Dr. Reddys, a leading multinational pharmaceutical company today announced the commercial launch of 2-deoxy-D-glucose (2-DG). Dr. Reddy's will supply to major Government as well as private hospitals across the country.
In the initial weeks, the Company will make the drug available in hospitals across metros and Tier 1 cities, and subsequently expand coverage to the other parts of the country.
Dr Reddy's today tweeted, "Dr. Reddy's announces the commercial launch of 2DGâ„¢."
The 2-DG manufactured by Dr. Reddy's has a purity of 99.5 per cent and is being sold commercially under the brand name 2DGTM. The maximum retail price (MRP) of each sachet has been fixed at Rs 990, with a subsidized rate offered to Government institutions. Enquiries for 2DGTM can be sent to [email protected].
2-DG was developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a laboratory of the Defence Research and Development Organisation (DRDO), in collaboration with Dr. Reddy's. 2-DG is an oral drug. It can be administered only upon prescription and under the supervision of a qualified physician to hospitalised moderate to severe COVID-19 patients as an adjunct therapy to the existing standard of care. Emergency use approval for anti-COVID-19 therapeutic application of the drug was granted on May 1, 2021.
Dr. G. Satheesh Reddy, Secretary Department of Defence (R&D) and Chairman, DRDO said: "We are pleased to have worked closely with our long-term industry partner Dr. Reddy's Laboratories, Hyderabad, for testing 2-DG as a therapeutic application in the treatment of COVID-19 patients. DRDO has been contributing in the fight against COVID-19 pandemic with its spin-off technologies."
Satish Reddy, Chairman, Dr. Reddy's said: "2-DG is yet another addition to our COVID-19 portfolio that already covers the full spectrum of mild to moderate and severe conditions and includes a vaccine. We are extremely pleased to have partnered with DRDO in our collective fight against the COVID-19 pandemic."
